The MIRApeel™ Fractional Transbrasion System Launches in the USA

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Irrimax Receives FDA Clearance for Irrisept

"This new clearance from the FDA further solidifies Irrisept as the market leader in wound irrigation," said Mark Alvarez, CEO of Irrimax.

As reported by eMIRAmed USA, LLC, MIRApeel™, is an aesthetic device which uses a new comprehensive 3D Skin Desquamation technology called “Fractional Transbrasion” to address a range of visible skin issues and the effects of premature aging.

Skincare professionals will experience a hands-on demonstration of just what sets this system apart at the American Academy of Dermatology meeting.  This latest skin rejuvenation technology was first developed and introduced in Germany and has quickly gained credibility among early-adopting dermatologists throughout Europe. This success led to a strong interest in the United States which caused the makers to accelerate their plans to register with the US FDA and make this system available here.

“The 2018 Annual Meeting of The American Academy of Dermatology is the perfect forum to showcase the comprehensive patient and client socio-demographic range, encompassing different skin types and skin conditions that can be directly addressed and improved with the MIRApeel™ treatments.

“The MIRA high-tech benefits of faster treatment sessions is more convenient and comfortable for clients and increases their satisfaction which readily translates into faster monetization and return on investment for users.”

“The real and most distinctive features of this offering are the MIRArollers – the special wet micro-needles – the MIRAbrasor and the serums,” says Serge Castro, President of eMIRAmed USA, LLC.

“We are ready to fully explore expanded distribution channels, build our sales presence, and strike meaningful associations with complementary aesthetic product manufacturers.”

“The new MIRApeel™  is being experienced by a growing number of patients, clients and physicians across Europe and will be presented to physicians during the AAD meetings as well.”

The MIRA family of technologies includes the MIRApeel™, the newly developed MIRAbrasor™ and MIRAroller™ attachments and a series of MIRAjolie™ serums. This range will be exclusively available to dermatology, cosmetic surgery and medical spa physicians throughout the United States.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles